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Abstract: 
Gastric cardia cancer (GCC), which occurs at the gastric-esophageal boundary, is one of the most 
malignant tumors. Despite its high mortality and morbidity, the molecular mechanism of 
initiation and progression of this disease is largely unknown. In this study, using proteomics and 
metabolomics approaches, we found that the level of several enzymes and their related metabolic 
intermediates involved in glucose metabolism were deregulated in GCC. Among these enzymes, 
two subunits controlling pyruvic acid efflux, lactate dehydrogenase A (LDHA) and pyruvate 
dehydrogenase B (PDHB), were further analyzed in vitro. Either down-regulation of LDH 
subunit LDHA or overexpression of PDH subunit PDHB could force pyruvic acid into the Krebs 
cycle rather than the glycolysis process in AGS gastric cancer cells, which inhibited cell growth 
and cell migration. Our results reflect an important glucose metabolic signature, especially the 
dysregulation of pyruvic acid efflux in the development of GCC. Forced transition from 
glycolysis to the Krebs cycle had an inhibitory effect on GCC progression, providing potential 
therapeutic targets for this disease.  
 
 
Article: 
Gastric cardia cancer (GCC),1 which occurs at the gastric-esophageal boundary, is one of the 
most malignant tumors. Despite the steadily falling incidence of gastric non-cardia cancer in the 
past two decades (1), the rate of GCC has risen rapidly, establishing gastric cancer as the second 
major cause of cancer-related deaths throughout the world (2). GCC has become a significant 
cause of mortality and morbidity both in the west (3–5) and in Asia (6, 7), especially in China 
(8). Although this cancer has become an important health problem worldwide, the its 
pathogenesis has not been well characterized (1). Most patients are diagnosed at an advanced 
stage, contributing to the high mortality rate of the disease.  
 
Systematic proteomics analysis has proved to be a powerful approach in a variety of human 
cancer research, including lung (9), esophagus (10), gastric (11), liver (12), breast (13), and brain 
cancer (14). Metabolomics, another new bio-omics technology recently introduced into cancer 
research (15), is the global analysis of the small metabolites produced by normal or pathologic 
cellular processes. Some metabolic intermediates have been identified as new cancer biomarkers 
(16).  
 
Using proteomics and metabolomics methods in this study, we found that a series of proteins and 
metabolic intermediates, mainly involved in glucose metabolism, were altered during the 
development of GCC. The high activity of anaerobic glycolysis and the impairment of aerobic 
respiration occurring in these cells recapitulated the Warburg effect (17). Further studies using a 
gastric cancer cell line demonstrated that the predominant anaerobic glycolysis was essential for 
tumor cells to sustain rapid proliferation, whereas forced transition from anaerobic glycolysis to 
aerobic respiration inhibited the growth of tumor cells. In conclusion, our study revealed the 
major metabolic alterations essential for the development of GCC and discovered a biomarker 
signature of GCC. Such a finding has the potential to improve early diagnosis and prognosis and 
helps to identify new therapeutic targets.  
 
MATERIALS AND METHODS 
Patients 
All GCC tissues and corresponding non-cancerous gastric cardia tissues were obtained from 
patients treated at the First Affiliated Hospital of Zhengzhou University (Henan, China) with 
written consent from the patients. Our study was approved by the Ethics Committee Board of 
Zhengzhou University. TNM classification, according to the criteria of the American Joint 
Committee on Cancer and the International Union against Cancer, was used by pathologists to 
stage the tumors (18). The corresponding non-cancerous tissues were resected 5 cm away from 
the cancer tissues from the same patient. All the samples were quickly frozen by liquid nitrogen 
and then kept at −80 °C. The basic histopathologic variables are summarized in Table I.  
 
Proteomics Analysis 
Five pairs of matched samples, randomly selected and mixed according to their differentiation 
level or lymph node metastasis status, were crushed and dissolved in lysis buffer (7 m urea, 2 m 
thiourea, 4% CHAPS, 0.5% IPG buffer, 3–10 NL, 0.5% Triton) containing protease inhibitor 
mixture. The process of two-dimensional gel separation and protein identification was carried 
out as described previously (10). The peptides were generated by trypsin. Keratin and trypsin 
peptide peaks were excluded from analysis. Both ESI-TOF and MS/MS spectra were processed 
by Analysis QS 1.1 Build 9865 (Applied Biosystems) and were searched using Mascot 1.6b13 
(Matrix Science). All spectra were searched against the mass spectrometry protein sequence 
database (MSDB) from the National Center for Biotechnology Information (release date, 
September 8, 2006; including 3,239,079 sequences). The following parameters were used for the 
searches: one missed and/or nonspecific cleavage permitted; mass tolerance for precursor ions, 
±0.2 Da; mass tolerance for fragment ions, ±0.5 Da; MS/MS filtering: reject spectra if less than 
10 peaks or precursor <50 or precursor >10,000. Probability-based Mowse score was used as the 
tool to determine whether the hit was a random event.  
 
 
Table I: Histopathological characteristics of 65 samples selected for analysis (proteomics and 
metabolomics analysis, RNA, and protein validation) 
Characteristic No. of patients 
Gender  
Female 7 
Male 58 
Age  
<60 33 
≥60 32 
Tumor size (cm3)  
<5 10 
≥5 55 
Tumor differentiation  
Moderate 42 
Poor 23 
Tumor infiltration depth  
≤T3 21 
T4 44 
Lymph node metastasis  
N0 11 
N1 54 
TNM stage  
I 3 
IIa 16 
IIb 6 
III 40 
 
 
Metabolite Profiling 
50 mg of tissue samples were pulverized after being frozen in liquid nitrogen with the addition of 
250 μl of mixed solvent (chloroform:methanol:water, 1:2:1, v/v/v). The lysate was ultrasonicated 
for 1 min and centrifuged at 12,000 rpm for 10 min. A total of 150 μl of aqueous supernatant was 
transferred to a GC vial containing two internal standards, l-2-chlorophenylalanine (10 μl, 0.3 
mg/ml) and heptadecanoic acid (10 μl, 1.0 mg/ml). The deposit was rehomogenized with a T10 
basic homogenizer (IKA, Staufen, Germany) for 30 s at 0 °C after adding 250 μl of methanol. 
After a second centrifugation, another 150-μl aliquot of supernatant was added to the mixture in 
the GC vial and vacuum-dried. Following the derivatization process, GC-TOF MS spectral 
acquisition and data analysis were performed according to the procedure described previously 
(19) with some modifications. Details of the method are provided in the supplemental material.  
 
RNA Isolation and Real Time PCR 
Total RNA was extracted from GCC specimens and their matched normal counterparts using 
TRIzol according to the standard protocol. 2 μg of RNA were processed directly to cDNA using 
a reverse transcription kit (Promega, Madison, WI) according to the manufacturer's instructions. 
Amplification reactions were performed in a 15-μl volume with 0.2 μl of SYBR Green. All of 
the reactions were performed in triplicate using an iCycler iQ System (Bio-Rad). To confirm the 
specificity of amplification, PCR products from each primer pair were subjected to a melting 
curve analysis and subjected to electrophoresis using a 2% agarose gel. POLR2A was used as an 
internal control for normalization. The relative gene expression level of each pair of GCC 
samples was calculated as described previously (20). The primers used in the experiments are 
listed in Table II.  
 
Table II: Primers used for real time PCR 
Gene Primer sequences 
ALDOA CCCCAAGTTATCAAATCC, GAAGTCAGCTCCGTCCT 
GAPDH ATGTTCGTCATGGGTGTGAA, GTCTTCTGGGTGGCAGTGAT 
ENO1 CAGGTCTGGGAAGTATGA, GCGATCCTCTTTGGGT 
Pyruvate kinase isozymes M2 isoform 1 (PKM2a) TGGAGAAACAGCCAAAG, GGCGGAGTTCCTCAAAT 
Pyruvate kinase isozymes M2 isoform 2 (PKM2b) GTGCGAGCCTCAAGTCA, ACGTGGGCGGTATCTGG 
LDHA TGAATGTTGCTGGTGTC, GTAGCCTTTGAGTTTGAT 
LDHB CTAGATTTCGCTACCTTAT, TCATTGTCAGTTCCCATT 
PDHB GTGATAAATATGCGTACCATTAGACC, CAGCACCAGTGACACGAACAGC 
ACO2 CCACCACTTCCGTGTTCC, CACCTTGCCCACTTCTGC 
FH GTGAACTAAAGGTGCCAAAT, CATACCACGAGAGGAAAATG 
MDH GCTCGAAAACTATCCAGTG, TAGGGAGACCTTCAACAAA 
UQCRC1 GGGAGATGCAGGAGAATGAT, TCTGGGCGAGGTCTAACAGT 
IDH1 GAAGAAGGTGGTGGTGTTGCC, CTGGGACTTGTACTGCTTGTCATAT 
Polymerase (RNA) II (DNA-directed) polypeptide A (POLR2A) GCAGGACGTAATAGAGG, CGGACACGACCATAGA 
 
 
Western Blot 
Proteins concentrations of samples extracted from tissue specimens and cell lines using 
radioimmune precipitation assay lysis buffer were determined using Bradford reagent (Sigma) 
according to the manufacturer's instructions. Western blot analysis was carried out by standard 
protocol. The following antibodies were used: murine anti-α-enolase (ENO1) (1:2000) from 
Abnova Corp., rabbit anti-lactate dehydrogenase A (LDHA) (1:1000) and -LDHB (1:1000) from 
Epitomics, and rabbit anti-aconitate hydratase (ACO2) (1:1000) from Proteintech Group Inc.  
 
Cell Culture 
Gastric cancer cell line AGS was obtained from the Cell Bank of Type Culture Collection of the 
Chinese Academy of Sciences (Shanghai Institute of Cell Biology, Chinese Academy of 
Sciences) and cultured in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine 
serum and 10 units/ml penicillin-G at 37 °C in a humidified atmosphere containing 5% CO2.  
 
Establishment of AGS/Pyruvate Dehydrogenase B (PDHB) Stable Cell Line 
The pcDNA3.1-PDHB and pcDNA3.1 plasmids were transfected into AGS cells using FuGENE 
reagent. The transfected cells were selected in the presence of G418 (800 μg/ml), and after 2 
weeks of selection, single clones were isolated for further analysis.  
 
RNA Interference of LDHA 
Target sequences of small interfering RNA (siRNA) for LDHA as well as a randomly aligned 
sequence used as negative control are listed in supplemental Table S1. FG12 lentiviral vector 
was used to produce double-stranded siRNA to inhibit LDHA expression in AGS cells; the 
information and usage of this vector system have been described previously (21).  
 
High Performance Liquid Chromatography Analysis of Lactic Acid 
Supernatants and cell lysis, respectively, were collected after the cells were grown for 2 days. 
Three volumes of methanol were added to remove protein from the samples above. After 
centrifugation and filtration through 0.22-μm PVDF membrane, a 20-μl aliquot of supernatant 
was injected into an Agilent 1100 instrument. Separation was achieved on an Agilent Zorbax 
Extend C18 column (4.6 × 250 mm, 5 μm) with phosphate buffer (100 mm NaH2PO4 in 0.01 m 
H3PO4, pH 2.5) containing 5% acetonitrile as the mobile phase at a constant flow rate of 0.8 
ml/min at 25 °C. The total time of separation was 7 min, and lactic acid was detected by a diode 
array detector at 210 nm at about 3.7 min. The relative level of lactic acid was normalized to the 
corresponding control samples according to their peak area.  
 
MTT and Soft Agar Assay 
For cell growth analysis, equal numbers of cells were seeded in 48-well plates. Cell numbers 
were measured by MTT assay according to the manufacturer's protocol (Roche Applied Science) 
every 2 days. For the clonogenic assay, cells were plated into 24-well, flat bottom plates using a 
two-layer soft agar system with 2000 cells/well in a volume of 400 μl/well as described 
previously (22). After 7 days of incubation, the colonies were counted and measured.  
 
Statistical Analysis 
SPSS 13.0 for Windows was used for statistical analysis, and data are expressed as mean ± S.E. 
Statistically significant differences were determined by Student's t test, one-way analysis of 
variance, and bivariate correlation analysis where appropriate and defined as p < 0.05 (*) and p < 
0.01 (**).  
 
RESULTS 
Proteomics Analysis of GCC 
To identify proteins involved in either initiation or progression of GCC, protein expression 
profiles were compared between pooled cancer and corresponding normal tissues, which were 
mixed according to the status of either tumor differentiation or lymph node metastasis. After 
two-dimensional gel separation and subsequent profile analysis, we identified a series of proteins 
with changes in their expression level (Fig. 1, A–D). ENO1 and LDHB were two representative 
spots on the gels indicating different intensity between cancer tissues and their corresponding 
normal counterparts (Fig. 1E and supplemental Fig. S1). Our results identified 44 protein spots 
produced by 38 genes whose expression showed an association with the degree of tumor 
differentiation. Furthermore, 29 protein products of 25 genes were differentially expressed 
during the process of tumor metastasis (Table III and supplemental Table S2). The expression of 
17 proteins from 15 genes was closely related to the status of both tumor dedifferentiation and 
tumor metastasis, indicating that these proteins play important roles in tumor progression and 
providing new candidates for early disease detection and prediction. These differentially 
expressed proteins participate in a variety of cellular functions, which could be classified into 
seven categories: cytoskeletal organization, cell proliferation, apoptosis, signal transduction, 
protein chaperone, metabolic enzymes, and proteins with other functions.  
 
Metabolite Profiling of GCC 
Alterations of metabolic enzymes were the prominently detected major changes in the 
proteomics analysis. These changes spanned from lipids to amino acids, especially glucose 
metabolism, suggesting that the tumor cells had acquired totally different metabolite profiles 
compared with their normal cellular counterparts. The metabolite profiles of 40 paired GCC 
samples underwent further analysis to identify the metabolic intermediates showing changes 
consistent with the related enzymes.  
Figure 1: An overview of two-dimensional gel images between GCC samples and corresponding 
normal samples.  
 
A–D, representative images of a two-dimensional gel for normal (left) versus cancer (right) tissues with poor 
differentiation (top) or with lymph node metastasis (bottom), respectively. Numbers indicated on the map highlight 
several of the protein spots that had differential expression. E, detailed alteration patterns of two glycolytic enzymes, 
ENO1 and LDHB, in different pooled samples.  
 
 
Typical GC-TOF MS methods were used to analyze the samples from both GCC and normal 
tissues (Fig. 2A), and in total, 223 variables were introduced to the subsequent analysis. The 
OPLS-DA model provided optimal modeling and predictive abilities with one predictive 
component and two orthogonal components (R2Ycum > 0.875, Q2cum > 0.7), achieving a distinct 
separation between the metabolite profiles of the two groups (Fig. 2B and supplemental Fig. S2). 
Significant differences were confirmed in a total of 44 metabolites involved in the metabolism of 
glucose, lipid, amino acids, nucleic acids, and vitamins. As shown in supplemental Table S3, 30 
metabolites were up-regulated in cancer tissues, whereas 14 were down-regulated compared with 
their matched normal tissues.  
 
 
 
 
 
 
Figure 2: Results from GC-TOF MS analysis 
 
A, typical total ion current chromatograms of tissue samples obtained from a GCC specimen and its matched normal 
counterparts. The total ion current chromatogram for the normal tissues is shown below the GCC samples. B, OPLS-
DA score plot discriminating the tissue samples from the GCC specimen and its matched normal counterpart using 
GC-TOF MS analysis.  
 
Unique Glucose Metabolism in GCC 
As revealed by proteomics analysis, 11 glucose metabolic enzymes identified from 13 spots 
showed different expression levels between cancer and normal tissues (Table III). These 
important enzymes in glycolysis, including fructose-1,6-diphosphate aldolase A (ALDOA), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and ENO1, exhibited an elevated 
expression level in the cancer cells. In contrast, five enzymes involved in the Krebs cycle and 
oxidative phosphorylation were remarkably down-regulated in cancer tissues, including PDHB, 
ACO2, fumarate hydratase (FH), malate dehydrogenase (MDH), and ubiquinol-cytochrome-c 
reductase core protein I (UQCRC1). Another enzyme in the Krebs cycle, isocitrate 
dehydrogenase (IDH1), also showed a slightly decreased expression level in the cancer cells. 
Additionally, the enzyme LDHB was down-regulated in GCC. This enzyme normally performs a 
major function in aerobic pathways transforming lactate to pyruvic acid (23).  
 
 
 
 
Table III:  Differentially expressed proteins involved in glucose metabolism in gastric cardia cancer compared with 
normal tissues  
Spot 
no. Protein ID 
Accession 
no. 
Theoretical 
molecular 
mass 
(kDa)/pI 
Experimental 
mass 
(kDa)/pI 
Peptides 
matched 
Sequence 
coverage 
Total 
score 
Differential ratio 
Function Tumor differentiation 
 Lymph node 
metastasis 
M P  N0 N1 
      %        
G1 Fructose-bisphosphate 
aldolase (EC 4.1.2.13) 
AAA51697 39.4/8.2 32/8.2 1 3.8 61 3 2.1  6.6 4.4 Glycolysis 
G2 Glyceraldehyde-3- 
phosphate 
dehydrogenase (EC 
1.2.1.12) 
AAA52496 36.05/8.73 33/8.4 1 4.2 97 2.1 5.8  3.8 4.8 Glycolysis 
G3 2-phospho-d-glycerate 
hydrolyase (EC 
4.2.1.11) 
AAA52387 47.2/7.46 42/6.5 2 7.1 130 3.9 2.9  1.1 3.4 Glycolysis 
G4 Pyruvate kinase 
isozymes M1/M2 (EC 
2.7.1.40) 
AAA36672 58/7.7 58/8.5 2 4.5 126 -2.6 -3  -11.8 -5.9 Glycolysis 
G5 Pyruvate kinase 
isozymes M1/M2 (EC 
2.7.1.40) 
AAA36672 58/7.7 36/6.0 3 7.7 224 4 1.8  NA NA Glycolysis 
G6 l-Lactate 
dehydrogenase B (EC 
1.1.1.27) 
NP_002291 36.6/5.9 37/5.5 4 15.8 247 -3 -2  -1.4 -2.1 Anaerobic 
respiration 
G7 Pyruvate 
dehydrogenase 
(lipoamide) (EC 
1.2.4.1) 
NP_000916 39.2/6.6 38/5.0 2 8.9 116 -0.9 -3  NA NA Krebs cycle 
G8 Aconitate hydratase 
(EC 4.2.1.3) 
CAI17931 85.4/7.6 85/8.5 5 7.1 289 NA NA  -9.7 -16.9 Krebs cycle 
G9 Aconitate hydratase 
(EC 4.2.1.3) 
CAI17931 85.4/7.6 85/8.2 7 11.5 470 NA NA  -6.4 -6.8 Krebs cycle 
G10 Isocitrate 
dehydrogenase (EC 
1.1.1.42) 
NP_005887 46.6/7.0 46/7.0 5 11.8 219 1 -1.5  NA NA Krebs cycle 
G11 Fumarate hydratase 
(EC 4.2.1.2) 
CAI13908 54.6/9.2 50/9.0 3 7.8 239 NA NA  -2.8 -2.8 Krebs cycle 
G12 Malate dehydrogenase 
(EC 1.1.1.37) 
CAG33686 36.4/7.4 36/7.2 3 8.7 106 -10.4 -3.9  NA NA Krebs cycle 
G13 Ubiquinol-
cytochrome-c 
reductase (EC 
1.10.2.2) core protein 
I 
EAW64898 52.6/6.4 52.0/6.0 3 6 144 -2.5 -2.3  NA NA Oxidative 
phosphorylation 
NA, not applicable; ID, identity; M, Modest; P, Poor. 
 
 
Further metabolomics study discovered that six intermediates in the glucose metabolism were 
changed during tumorigenesis (Table IV). As expected, fructose (fructose 6-phosphate and 
fructose 1,6-diphosphate), glyceraldehyde (glyceraldehyde 3-phosphate), and pyruvic acid 
produced during glycolysis were elevated in the tumor samples, and the end product of anaerobic 
pathway, lactic acid, was also increased. Fumaric acid produced by the Krebs cycle was 
decreased, which was consistent with down-regulation of fumarate hydratase. However, another 
product in the Krebs cycle, isocitric acid, was greatly enhanced in the tumor samples. The higher 
isocitric acid level was presumably due to the difference in metabolic rate from citrate to α-
ketoglutarate involving citrate synthase. The conversion of isocitric acid to ketoglutarate and 
then to succinyl-CoA is relatively slow because it is the critical step to build up NADH, causing 
the accumulation of isocitric acid. In general, the integrated results from proteomics and 
metabolite profiling clearly revealed that, unlike normal cells, glycolysis followed by anaerobic 
respiration was utilized as the major pathway to metabolize glucose in GCC cells, whereas the 
Krebs cycle and oxidative phosphorylation were impaired.  
 
Table IV: Differential metabolites associated with glycometabolism derived from OPLS-DA 
mode of GC-TOF MS analysis with t test 
No. Retention (min) Metabolitea -Fold changeb,c pc VIPd 
1 5.22 Pyruvic acid 1.20 0.12  
2 5.37 Lactic acid 1.14 2.01 × 10−3 1.13 
3 7.47 Glyceraldehyde 2.21 3.22 × 10−3 1.12 
4 9.54 Fumaric acid 0.86 0.03  
5 15.55 Isocitric acid 1.40 1.64 × 10−5 1.13 
6 16.25 d-Fructose 1.93 1.69 × 10−4 1.37 
a Metabolites were identified by comparing the exact mass and retention time of our reference metabolites in our laboratory.  
b -Fold change with a value >1 indicates a relatively higher concentration present in GCC patients, whereas a value <1means a relatively lower 
concentration as compared with the healthy controls.  
c -Fold change and p value were calculated from a non-parametric t test.  
d Variable importance in the projection was obtained from OPLS-DA with a threshold of 1.0.  
 
 
Validation of Glucose Metabolic Characteristics in Additional GCC Patients: RNA and 
Protein Levels of Key Pathways 
To extend our initial observations of changes in the glucose metabolism of GCC, RNA and 
protein levels of the corresponding genes were examined by real time PCR and Western blot of 
additional GCC patients. Because the isoenzymes of PKM2 (M1 and M2; labeled as PKM2a and 
PKM2b in the following) and the subunits of LDH (LDHA and LDHB) may play different roles 
in cancer, the mRNA levels of both PKM2 isoenzymes and LDHA were measured. When 
compared with matched normal gastric cardia samples, six of the seven glycolytic enzymes 
(combined with LDHA and LDHB for ease of analysis) were significantly overexpressed with the 
exception of LDHB, which was obviously down-regulated (Fig. 3A). However, most enzymes in 
the Krebs cycle (combined with UQCRC1 for the same reason) were greatly down-regulated in 
GCC with the exception of IDH1 and FH, which were only slightly decreased (Fig. 3B). 
Moreover, a significant correlation was found between the change in levels of relative mRNA 
expression and the expression ratio of the same protein identified in the two-dimensional gel 
(Fig. 3C), adding to our knowledge that these enzyme levels were truly altered in GCC. 
Nevertheless, no significant relationship was detected between the mRNA expression of these 
target genes and the clinical features of GCC (supplemental Table S4), which may indicate that 
such metabolic conversions might happen in the early stage of tumorigenesis.  
 
On the other hand, the protein expression levels of ENO1, LDHA, LDHB, and ACO2 were 
analyzed by Western blot (Fig. 3D). ACO2 showed decreased expression in seven of eight cancer 
samples, whereas the level of ENO1 was increased in six of eight cancer samples compared with 
their normal counterparts. Due to the high homology of LDHA and LDHB, the antibodies could 
not distinguish the two bands clearly on the gel. Thus, we differentiated the two bands using 
specific siRNA to knock down either LDHA or LDHB, which facilitated the identification of 
each band successfully. As shown in supplemental Fig. S3, the upper band was LDHB, whereas 
the lower band was LDHA. Seven of eight cancer samples showed LDHA overexpression, and 
six of eight tumor tissues had decreased expression of LDHB. Notably, none of the GCC samples 
had a normal glucose metabolic pathway; each had an abnormality in one or several steps in this 
process, which might facilitate the early detection of GCC.  
 
Figure 3: Validation of glucose metabolic characteristics in GCC from RNA to protein level  
 
A and B, relative mRNA expression of seven glycolysis- and anaerobic respiration-related genes and six Krebs 
cycle- and oxidative phosphorylation-related genes in 33 pairs of matched human GCC and corresponding normal 
tissues by quantitative real time PCR. The mRNA expression level was normalized to that of RP2; and each box plot 
shows the distribution of the relative expression level of the corresponding gene individually. Error bars, maximum 
and minimum values except for the outlier represented as an open circle in the figure. C, scatter plots demonstrating 
the concordance between the protein expression level from proteomics analysis and the RNA expression level given 
by real time PCR. D, protein expression level of ACO2, ENO1, LDHA, and LDHB in randomly selected eight pairs 
of matched human GCC and corresponding normal tissues using Western blot. Ponceau S staining was used as a 
loading control. 2D, two-dimensional gel; T, tumor; N, normal.  
 
 
Fate of Pyruvic Acid Regulated by LDH and PDH Is Intrinsically Intertwined with Survival of 
Cancer Cells 
One metabolic characteristic of GCC discovered from our results was that more pyruvic acid was 
transformed into lactic acid, rather than acetyl-CoA, following the Krebs cycle. We speculated 
that the ratio of the two enzyme complexes, LDH and PDH, determined the fate of pyruvic acid, 
which changed the glucose metabolism pathway and influenced the cell transformation process. 
When LDHA was knocked down by siRNA (Fig. 4A), the activity of LDH to catalyze pyruvic 
acid (supplemental Fig. S4A) and produce lactic acid (Fig. 4B) dramatically decreased, which 
further confirmed the effect of siRNA in these function assays. Meanwhile, a zymogram of the 
LDH isoenzyme pattern showed that in LDHA knockdown cells the intensities of the five bands 
obviously shifted from LDH5 (A4) to LDH1 (B4) (supplemental Fig. S4B), which was found to 
be consistent with diminished enzymatic activity. The MTT assay revealed that these LDHA 
knockdown cells grew much slower than the control cells (Fig. 4C). Moreover, LDHA 
knockdown cells formed fewer colonies in soft agar (Fig. 4D) and also had a relatively impaired 
ability to migrate in a Boyden chamber (supplemental Fig. S5). We concluded that an 
overexpression of LDHA and high activity of LDH complex were necessary for tumor cells to 
sustain rapid proliferation and migration. In contrast, in vitro stable overexpression of PDHB 
(Fig. 4E) (a subunit of PDH complex that was down-regulated in GCC as mentioned above) 
diverted more pyruvic acids to the Krebs cycle and caused an impairment in the production of 
lactic acid (Fig. 4F), resulting in cell growth inhibition (Fig. 4G) and a decrease in the ability to 
form colonies in soft agar (Fig. 4H). Interestingly, overexpression of PDHB had almost no effect 
on cell migration (supplemental Fig. S5), which was slightly different from knockdown of 
LDHA, although both of them resulted in the increasing conversion from acetyl-CoA to pyruvic 
acids. In conclusion, transforming more pyruvic acids to lactic acids by GCC cells was necessary 
to sustain their rapid proliferation and was controlled by the levels of LDH and PDH.  
 
Figure 4: LDH and PDH influence cancer cell growth by controlling the fate of pyruvic acid.  
 
A, Western blot analysis showed RNAi-mediated knockdown of LDHA in AGS. Equal loading was ascertained 
using tubulin as an internal control. B, HPLC analysis indicated the decrease of lactic acid in both supernatant and 
cytoplasm of cells with LDHA knockdown. C, MTT assay showed the effect of LDHA gene silencing on cell 
growth of AGS. D, soft agar assay showed the effect of LDHA gene silencing on colony formation of AGS in vitro. 
E, Western blot analysis showed overexpression of PDHB in AGS. F, HPLC analysis indicated the decrease of 
lactic acid in both supernatant and cytoplasm of cells with PDHB overexpression. G, MTT assay showed the effect 
of PDHB overexpression on cell growth of AGS. H, soft agar assay showed the effect of PDHB overexpression on 
colony formation of AGS in vitro. All the experiments were performed in triplicate and expressed as mean ± S.E. *, 
p < 0.05; **, p < 0.01.  
 
DISCUSSION 
In the last two decades, the incidence of GCC, or proximal gastric cancer, has increased almost 
all over the world (24–26), including China (27). This cancer is often diagnosed late in its course 
and is often fatal. Little progress has been achieved in the prevention and treatment of this 
disease because of the lack of an effective and sensitive diagnostic biomarker as well as 
knowledge of its etiology (28). Therefore, systematic research of GCC is required to better 
understand its molecular pathogenesis.  
 
In this study, we first discovered the comprehensive differences of proteins and metabolic 
intermediates between paired normal and GCC samples, especially those involved in glucose 
metabolism. Glucose is the major source for energy production and macromolecule biosynthesis 
to maintain continuous rapid proliferation of tumor cells (29). Many groups have demonstrated 
that a variety of solid tumors, including renal (30), colon, stomach (31), and breast (32), prefer 
anaerobic glycolysis to the Krebs cycle for energy production even under normoxia, or the 
Warburg effect (17). In our study, we also found a predominance of anaerobic glycolysis, rather 
than the Krebs cycle, in GCC at different levels, spanning from RNA to protein to the 
corresponding metabolic intermediates, thus validating that the Warburg effect also exists in 
GCC (Fig. 5A). Several enzymes involved in the glycolysis are considered ubiquitously 
overexpressed in a variety of cancers, such as ENO1, GAPDH, and PKM (33), which is 
consistent with our observation in GCC. A high level of glycolysis endows cancer cells with a 
growth advantage, which enhances unconstrained proliferation and invasion. As for the enzymes 
involved in the Krebs cycle, the situation is more complicated, depending on the cancer type. 
Succinate dehydrogenase (SDH) and FH are often dysregulated in renal cancer, both of which 
are associated with hypoxia-inducible factor (HIF) activation (34). Genes encoding enzymes, 
such as IDH1, have been found frequently mutated, demonstrating early genetic alterations in 
glioma (35). The activity of ACO2 is usually elevated in prostate cancer, promoting the 
transformation of normal citrate-producing epithelial cells to malignant citrate-oxidizing cells 
(36). However, ACO2 is often deleted in colorectal cancer (37). In our GCC samples, IDH1, 
ACO2, FH, and MDH were all down-regulated, which indicated an impaired Krebs cycle. Highly 
active glycolysis and an impaired Krebs cycle guarantee enough metabolic intermediates by 
avoiding thorough oxidation of glucose, which is essential for the synthesis of macromolecules, 
such as lipid, protein, and nuclear acid, during cell division (38–40). Moreover, the hypoxic 
environment in tumor tissues causes increased reactive oxygen species production (41, 42), 
which leads to severe oxidative damage and cell apoptosis, so that tumor cells often adopt 
impaired oxidative phosphorylation to evade such reactive oxygen species-mediated cell death 
(43). Our work revealed that the Warburg effect is also prevalent in GCC, spanning from genes 
to metabolites, suggesting that such metabolic transition is important for the development of 
GCC, and the glycolysis signature provides potential biomarker identification for clinical 
diagnosis of this intractable cancer.  
 
The balance between aerobic glycolysis and the Krebs cycle in cancer cells ensures the maximal 
and rapid production of both energy and metabolic intermediates for cell proliferation. Two 
enzyme complexes, LDH and PDH, control the metabolism of pyruvic acids, transforming them 
to either lactic acids or acetyl-CoA, then entering the Krebs cycle. The tetrameric LDH contains 
five isoenzymes formed by random association of two subunits, LDHA and LDHB, 
interconverting pyruvate and lactate with concomitant interconversion of NADH and NAD+ (44). 
The change of LDHB expression suggested by our two-dimensional gel analysis encouraged us 
to further examine the expression of LDHA in GCC. In contrast to the down-regulation of 
LDHB, LDHA was found to be overexpressed in GCC. Overexpression of LDHA has been 
previously reported to favor the formation of cathodic LDH (isoenzymes 4 and 5) and generation 
of lactate, which is often observed in solid tumors and correlated with advanced tumor grade, 
poor prognosis, VEGF up-regulation, and hypoxia (45–47). In our study, we also observed the 
influence of deregulated LDHA on the efflux of pyruvic acid. A knockdown of LDHA by siRNA 
resulted in a shift of LDH isoenzymes from Stages 3/4/5 to 1/2 with a concomitant significant 
decrease in catalytic activity as well as lactic acid production. Furthermore, a knockdown of 
LDHA could obviously hamper both anchorage-dependent and -independent growth of tumor 
cells, which is consistent with the previous study reporting that LDHA was essential for the 
transformation process (48, 49).  
 
Figure 5: Unique glucose metabolic characteristics in GCC may have potential as targets for 
cancer therapy 
 
A, the fingerprint map of the glucose metabolic network in GCC highlighting those enzymes and metabolic 
intermediates that are dysregulated. B, normal cells preferred the Krebs cycle and oxidative phosphorylation 
(OXPHOS) compared with anaerobic respiration. This favored pathway is controlled by the high activity of PDH 
and relatively low activity of LDH (left). GCC cells not only favor glycolysis by up-regulating the enzymes involved 
but also strongly prefer anaerobic respiration with production of prominent lactic acids rather than the Krebs cycle 
and oxidative phosphorylation because of activating LDH and suppressing PDH (middle). This divergence between 
GCC and normal tissues will give us new therapeutic opportunities (right). GAP, glyceraldehyde 3-phosphate; Lac, 
lactic acid; Pyr, pyruvate.  
 
 
The other pyruvic acid efflux controller, PDH multienzyme complex, catalyzes the first reaction 
of an oxidative decarboxylation sequence and converts pyruvate to acetyl-CoA and CO2. It has 
been reported that in various cancer types, such as lung (50) as well as head and neck squamous 
cancer (51), pyruvate dehydrogenase kinase induced by overexpressed HIF-1 phosphorylates and 
inactivates the PDH complex, inhibits the conversion of pyruvate to acetyl-CoA, and thereby 
attenuates mitochondrial function and respiration (52). In our study, we found that one of the 
components in PDH multienzyme complex, PDHB, was down-regulated in GCC, leading to 
decreased enzymatic activity and an impaired Krebs cycle. Consistent with our observation, 
overexpression of PDHB reduced lactate acid production and decreased the proliferation of 
tumor cells in both an anchorage-dependent and -independent manner. Thus, our study clearly 
demonstrated that LDHA and PDHB can determine the fate of pyruvic acid, anaerobic glycolysis 
or aerobic respiration, via the regulation of LDH and PDH complex, respectively. These studies 
have improved our understanding of the Warburg effect and its influence on GCC development 
and progression, and the metabolic pathway can serve as a potential target for GCC therapy (Fig. 
5B).  
 
Although either knockdown of LDHA or overexpression of PDHB promoted the conversion from 
acetyl-CoA to pyruvic acids, leading to the retardation of tumor growth, only LDHA but not 
PDHB affected cell migration, indicating that the corresponding molecules, such as lactic acid, 
pyruvic acid, and acetyl-CoA, might not influence cell migration directly, whereas other 
concomitant changes such as the ratio of NAD+/NADH might influence the cell migration. Of 
course, we cannot exclude that LDHA has its own special role in cancer cell migration except for 
its usual role in cell metabolism.  
 
This study highlighted several other proteins that expand our understanding of the molecular 
pathology of GCC. For example, selenium-binding protein 1 (SELENBP1) was significantly 
down-regulated in these cancers, consistent with the findings in colorectal (53), ovarian (54), and 
lung (55) cancers. Some investigators have suggested that selenium may have an 
anticarcinogenic property toward GCC (56). In addition, elevated levels of many metabolic 
intermediates of the nucleotide metabolism were noted that were also observed in previous 
reports (19, 57), indicating active nucleic acid turnover in tumor tissues. Also of interest, fatty 
acids were all down-regulated in the tumor samples examined, which was consistent with the 
dramatically decreased expression of lipase, gastric (LIPF). Down-regulation of lipase in GCC 
resulted in impaired triglyceride and phospholipid hydrolysis, leading to the lack of dissociative 
fatty acids. This was further confirmed by the decrease of another two intermediates (glycerol 
phosphate and myoinositol). As expected, a number of amino acids and their polyamine 
derivatives were increased in cancer tissues to meet the requirement of protein synthesis. A low 
expression level of the enzyme aspartate aminotransferase (AspT) was noted in our proteomics 
analysis of the GCC cells. This enzyme normally helps aspartate to enter the Krebs cycle through 
transamination. Large amounts of aspartic acid and asparagine in cancer tissues might result 
from impairment of this enzyme, diverting more aspartic acids to participate in the synthesis of 
purines as well as proteins rather than entering the impaired Krebs cycle.  
 
In summary, with the help of proteomics and metabolomics analysis, we discovered that a series 
of proteins and related metabolites in glucose metabolism showed an altered expression level in 
GCC tissues. These findings will not only benefit early diagnosis of this cancer at the molecular 
level but also improve our understanding of the initiation and development of GCC. A highly 
activated anaerobic glycolysis and an impaired aerobic respiration are important for maintaining 
the rapid proliferation of this cancer, which is achieved by highly active LDH concomitant with 
relatively inactivated PDH to divert more pyruvic acids into the anaerobic glycolysis pathway. 
Our fin dings suggest that an antagonist to LDH as well as an agonist of PDH may be a novel 
therapy for GCC.  
 
ABBREVIATIONS 
GCC   gastric cardia cancer 
LDH   lactate dehydrogenase 
PDH   pyruvate dehydrogenase 
TNM   Tumor, Node and Metastasis 
OPLS-DA  orthogonal partial least squares discriminant analysis 
ENO1   α-enolase 
ACO2   aconitate hydratase 
UQCRC1  ubiquinol-cytochrome-c reductase core protein I 
IDH1   isocitrate dehydrogenase 
PKM   pyruvate kinase, muscle 
FH   fumarate hydratase 
MDH   malate dehydrogenase 
HIF   hypoxia-inducible factor 
ALDOA  fructose-1,6-diphosphate aldolase A 
MTT   Methyl Thiazolyl Tetrazolium. 
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